Merck & Co., Inc. (MRK) - Moat Analysis

Business Model

25%

3.5/5

3.45

Merck's model is anchored by patented pharmaceuticals with high gross margins (~77% in FY2025) and a 54-year dividend history, but near-term visibility is strained by Keytruda's end-2028 U.S. patent expiry. Product concentration is extreme with Keytruda at roughly 49% of FY2025 revenue, and U.S. revenue is 56% of the total.

Sub-dimension

Summary

Score

Revenue Predictability30%

3.25

Forward visibility of revenue: backlog, contracts, retention

3.25

Summary

Prescription-drug revenue is recurring through reimbursement cycles, and FY2026 guidance of $65.5-$67.0B was disclosed alongside an identified $2.5B headwind from generics, IRA price setting, and the revised AstraZeneca Koselugo deal. Forward visibility drops sharply past 2028 when Keytruda U.S. exclusivity ends.

3.25

Product Diversification10%

2.25

Diversification across product lines, segments, and customers

2.25

Summary

Keytruda generated $31.68B of FY2025 total revenue of $65.01B, or roughly 49%, and around 55% of Pharmaceutical segment sales. Other $1B+ products (Gardasil, Bridion, Winrevair at $1.4B, Capvaxive at $759M, Animal Health at $6.35B) exist but do not offset single-asset concentration.

2.25

Geographic Diversification15%

2.75

Distribution across regions and home-market dependence

2.75

Summary

FY2025 revenue mix was U.S. 56.2% ($36.51B), EMEA 22.4% ($14.58B), Latin America 5.3%, Japan 4.2%, and China 3.0% ($1.94B, down from $5.49B in FY2024 on Gardasil weakness). U.S. dependence is above the typical mid-40s threshold for strong diversification.

2.75

Scalability20%

3.75

Ability to grow revenue without proportional cost increases

3.75

Summary

Pharmaceutical economics scale well once a drug is approved, with FY2025 gross margin of roughly 77% and operating margin around 34%. The model is constrained by continuous R&D and M&A reinvestment needed to refresh the portfolio (phase III pipeline has nearly tripled since 2021), which limits pure operating leverage.

3.75

Revenue Quality25%

3.75

Nature of the revenue: contractual vs transactional, defensive vs discretionary

3.75

Summary

A large share of revenue is mission-critical oncology and vaccine treatment that payers reimburse through long-standing public and private programs. Revenue is transactional rather than subscription-contractual, and payer mix exposes the company to Medicare and PBM negotiating leverage.

3.75

Competitive Advantages

40%

2.7/5

2.70

The moat is built on patent-protected innovation, with Keytruda as the defining advantage and FY2025 sales of $31.68B roughly triple Bristol-Myers' Opdivo at $10.05B. The weakness is that this advantage is time-boxed: the key U.S. patent expires at the end of 2028, biosimilars are already preparing to launch, and the subcutaneous Keytruda Qlex is management's explicit bridge strategy.

Sub-dimension

Summary

Score

Pricing Power30%

3.25

The company's ability to raise prices without losing customers

3.25

Summary

3.25

Switching Costs20%

2.75

How costly it is for customers to switch to a competitor

2.75

Summary

2.75

Network Effects20%

1.50

Whether the product becomes more valuable as more users join

1.50

Summary

1.50

Brand Strength15%

2.75

Degree to which brand drives premium pricing and loyalty

2.75

Summary

2.75

Innovation Barrier15%

3.75

How difficult it is for competitors to replicate the core technology

3.75

Summary

3.75

Full analysis requires login